At a J.P. Morgan media event Tuesday, the Gilead C-suite seemed to be walking on air as they highlighted Yeztugo’s capture of ...

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

Still riding the high of last year’s twice-yearly HIV PrEP approval of lenacapavir as Yeztugo, Gilead Sciences is approaching ...

The announcement of the cuts prompted warnings from around the world about the potential consequences. In the Journal of ...

The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2026, according to Statista. The oncology segment alone is expected to generate $232 billion in sales this year.

CVS is now covering long-acting injectable PrEP, representing a shift from last year when the pharmacy giant announced it was ...

Speaking at the J.P. Morgan Healthcare Conference 2026, CEO Daniel O’Day said that the company has seven pipeline drugs for ...

Pharmaceutical patent protection can be extended when drug companies bring newer products to market before their first patent ...

Seeking to prevent the spread of HIV, Unitaid is providing $31 million to South Africa and Zambia in hopes of widening access ...

After a flurry of Big Pharma deals in the first week of the new year, the life sciences industry is heading to San Francisco ...

In the most recent trading session, Gilead Sciences (GILD) closed at $122.59, indicating a +1.23% shift from the previous ...

Since my article from October, "What To Expect From Gilead in Q3 2025", Gilead Sciences' stock ( GILD) reached an all-time ...